miR-411 contributes the cell proliferation of lung cancer by targeting FOXO1

Tumor Biology

Volumn 37, Issue 4, 2016, Pages 5551-5560

  Zhao, Zhiju ^a   Qin, Limei ^b   Li, Shu ^c  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^c WANNAN MEDICAL COLLEGE   (China)

Author keywords

Cell proliferation; FOXO1; Lung cancer; miR 411

Indexed keywords

CYCLIN D1; MICRORNA; MICRORNA 411; PROTEIN P21; PROTEIN P27; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; FOXO1 PROTEIN, HUMAN; MIRN411 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ANCHORAGE DEPENDENT GROWTH; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FOXO1 GENE; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE REPRESSION; LUNG CANCER CELL LINE; MUTATIONAL ANALYSIS; PHASE TRANSITION; PRIORITY JOURNAL; UPREGULATION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; FORKHEAD BOX PROTEIN O1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS;

EID: 84947093526     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4425-8     Document Type: Article

References (38)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166.
2. McDoniels-Silvers AL, Nimri CF, Stoner GD, Lubet RA, You M. Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin Cancer Res: Off J Am Assoc Cancer Res. 2002;8(4):1127–38.
3. Jacks DATT. Modeling human lung cancer in mice: similarities and shortcomings. Oncogene. 1999;18:5318–24.
4. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006;9(6):485–95. doi:10.1016/j.ccr.2006.04.022.
5. Mahoney CL, Choudhury B, Davies H, Edkins S, Greenman C, Haaften G, et al. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer. 2009;100(2):370–5. doi:10.1038/sj.bjc.6604886.
6. To MD, Wong CE, Karnezis AN, Del Rosario R, Di Lauro R, Balmain A. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet. 2008;40(10):1240–4. doi:10.1038/ng.211.
7. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–6. doi:10.1038/nature05945.
8. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500. doi:10.1126/science.1099314.
9. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–60. doi:10.1056/NEJMoa031644.
10. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–8. doi:10.1016/S1470-2045(09)70364-X.
11. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12(11):1004–12. doi:10.1016/S1470-2045(11)70232-7.
12. Lam EWF, Brosens JJ, Gomes AR, Koo CY. Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer. 2013;13(7):482–95. doi:10.1038/Nrc3539.
13. Zhang X, Yalcin S, Lee DF, Yeh TYJ, Lee SM, Su J, et al. FOXO1 is an essential regulator of pluripotency in human embryonic stem cells. Nat Cell Biol. 2011;13(9):1092–U1118. doi:10.1038/Ncb2293.
14. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A. 2005;102(5):1649–54. doi:10.1073/pnas.0406789102.
15. Yamagata K, Daitoku H, Takahashi Y, Namiki K, Hisatake K, Kako K, et al. Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. Mol Cell. 2008;32(2):221–31. doi:10.1016/j.molcel.2008.09.013.
16. Wu L, Li H, Jia CY, Cheng W, Yu M, Peng M, et al. MicroRNA-223 regulates FOXO1 expression and cell proliferation. FEBS Lett. 2012;586(7):1038–43. doi:10.1016/j.febslet.2012.02.050.
17. Wu Z, Sun H, Zeng W, He J, Mao X. Upregulation of MircoRNA-370 induces proliferation in human prostate cancer cells by downregulating the transcription factor FOXO1. PLoS ONE. 2012;7(9), e45825. doi:10.1371/journal.pone.0045825.
18. Zhang L, Quan H, Wang S, Li X, Che X. MiR-183 promotes growth of non-small cell lung cancer cells through FoxO1 inhibition. Tumour Biol: J Int Soc Oncodev Biol Med. 2015. doi:10.1007/s13277-015-3550-8.
19. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33. doi:10.1016/j.cell.2009.01.002.
20. Ke J, Zhao Z, Hong SH, Bai S, He Z, Malik F, et al. Role of microRNA221 in regulating normal mammary epithelial hierarchy and breast cancer stem-like cells. Oncotarget. 2015;6(6):3709–21.
21. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9(3):189–98. doi:10.1016/j.ccr.2006.01.025.
22. Nadal E, Zhong J, Lin J, Reddy RM, Ramnath N, Orringer MB, et al. A microRNA cluster at 14q32 drives aggressive lung adenocarcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2014;20(12):3107–17. doi:10.1158/1078-0432.CCR-13-3348.
23. Harafuji N, Schneiderat P, Walter M, Chen YW. miR-411 is up-regulated in FSHD myoblasts and suppresses myogenic factors. Orapant Journal of Rare Diseases. 2013;8:55.
24. van Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, et al. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res:BCR. 2012;14(1):R34. doi:10.1186/bcr3127.
25. Gao Y, Xiao Q, Ma H, Li L, Liu J, Feng Y, et al. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci U S A. 2010;107(44):18892–7. doi:10.1073/pnas.1004952107.
26. Shen G, Jia H, Tai Q, Li Y, Chen D. miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma. Carcinogenesis. 2013;34(1):211–9. doi:10.1093/carcin/bgs320.
27. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–66. doi:10.1038/nrc2602.
28. van der Horst A, Burgering BMT. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol. 2007;8(6):440–50. doi:10.1038/Nrm2190.
29. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 2011;1813(11):1978–86. doi:10.1016/j.bbamcr.2011.03.010.
30. Massagué J. G1 cell-cycle control and cancer. Nature. 2004;432:9.
31. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol. 2000;20(23):8969–82.
32. Seoane J, Le HV, Shen L, Anderson SA, Massague J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 2004;117(2):211–23.
33. Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 2008;10, e19. doi:10.1017/S1462399408000744.
34. Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sellers WR. A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell. 2002;2(1):81–91.
35. Zhang WC, Liu J, Xu X, Wang G. The role of microRNAs in lung cancer progression. Med Oncol. 2013;30(3):675. doi:10.1007/s12032-013-0675-8.
36. Gao Y, Gao F, Ma JL, Sun WZ, Song LP. The potential clinical applications and prospects of microRNAs in lung cancer. OncoTargets Ther. 2014;7:901–6. doi:10.2147/OTT.S62227.
37. Marshall AD, Lagutina I, Grosveld GC. PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis. Cancer Res. 2011;71(24):7471–80. doi:10.1158/0008-5472.CAN-11-0924.
38. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol. 2007;18(5):460–6. doi:10.1016/j.copbio.2007.10.007.